WO2008084402A3 - Diagnosis and treatment of alzheimer's and other neurodementing diseases - Google Patents
Diagnosis and treatment of alzheimer's and other neurodementing diseases Download PDFInfo
- Publication number
- WO2008084402A3 WO2008084402A3 PCT/IB2008/000456 IB2008000456W WO2008084402A3 WO 2008084402 A3 WO2008084402 A3 WO 2008084402A3 IB 2008000456 W IB2008000456 W IB 2008000456W WO 2008084402 A3 WO2008084402 A3 WO 2008084402A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alzheimer
- treatment
- antibodies
- neurodementing
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK08719192.0T DK2104682T3 (en) | 2007-01-11 | 2008-01-11 | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES |
CA2675340A CA2675340C (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
JP2009545252A JP2010515717A (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of Alzheimer and other neurodementia disorders |
AU2008204335A AU2008204335B2 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
EP08719192.0A EP2104682B1 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
ES08719192.0T ES2610474T3 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of Alzheimer's disease and other neurodegenerative diseases causing dementia |
SI200831731A SI2104682T1 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88452607P | 2007-01-11 | 2007-01-11 | |
US88451307P | 2007-01-11 | 2007-01-11 | |
EP07000507A EP1944314A1 (en) | 2007-01-11 | 2007-01-11 | Diagnosis of Alzheimer's disease and other neurodementing disorders |
EP07000521.0 | 2007-01-11 | ||
US60/884,513 | 2007-01-11 | ||
EP07000507.9 | 2007-01-11 | ||
EP07000521A EP1944315A1 (en) | 2007-01-11 | 2007-01-11 | Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases |
US60/884,526 | 2007-01-11 | ||
US98167507P | 2007-10-22 | 2007-10-22 | |
US98166707P | 2007-10-22 | 2007-10-22 | |
US60/981,675 | 2007-10-22 | ||
EP07119002 | 2007-10-22 | ||
US60/981,667 | 2007-10-22 | ||
EP07119026 | 2007-10-22 | ||
EP07119002.9 | 2007-10-22 | ||
EP07119026.8 | 2007-10-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008084402A2 WO2008084402A2 (en) | 2008-07-17 |
WO2008084402A3 true WO2008084402A3 (en) | 2009-04-09 |
WO2008084402A8 WO2008084402A8 (en) | 2009-08-27 |
Family
ID=39609117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/000456 WO2008084402A2 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
Country Status (11)
Country | Link |
---|---|
US (3) | US7939075B2 (en) |
EP (1) | EP2104682B1 (en) |
JP (1) | JP2010515717A (en) |
AU (1) | AU2008204335B2 (en) |
CA (1) | CA2675340C (en) |
DK (1) | DK2104682T3 (en) |
ES (1) | ES2610474T3 (en) |
PL (1) | PL2104682T3 (en) |
SI (1) | SI2104682T1 (en) |
TW (1) | TW200844110A (en) |
WO (1) | WO2008084402A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090280114A1 (en) * | 2002-04-12 | 2009-11-12 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
PT1976877E (en) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
EP2143447A1 (en) * | 2008-07-11 | 2010-01-13 | Universität Konstanz | Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease |
EP2398500B1 (en) * | 2009-02-20 | 2019-03-13 | 2-BBB Medicines B.V. | Glutathione-based drug delivery system |
KR101095630B1 (en) * | 2009-06-17 | 2011-12-19 | 주식회사 이노파마스크린 | A method for screening a compound of inhibiting interaction between beta-amyloid and VEGF and beta-amyloid inhibitor thereof |
DE102009034119A1 (en) * | 2009-07-20 | 2011-01-27 | Philipps-Universität Marburg | Method, in particular enzyme-linked immunosorbent assay (ELISA), for in vitro detection of amyloid beta autoantibodies, microtiter plate and test kit |
EP3296295A1 (en) | 2009-08-07 | 2018-03-21 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
JP2013523182A (en) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | Amyloid beta-binding protein |
EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
RS53496B1 (en) * | 2011-10-04 | 2015-02-27 | Affiris Ag | Method for detecting ass-specific antibodies in a biological sample |
KR101190573B1 (en) * | 2011-10-07 | 2012-10-18 | 대한민국 | THE NOVEL A ß 22(pE)-42 PEPTIDE THAT BIND TO AMYLOID-BETA ANTIBODY SPECIFICALLY IN BLOOD AND PHARMACEUTICALLY COMPOSITION FOR THE DIAGNOSIS OF DEMENTIA DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT |
CN104662423A (en) * | 2012-03-13 | 2015-05-27 | 杨森阿尔茨海默氏症免疫治疗公司 | Oligomeric Abeta in the diagnosis, prognosis, and monitoring of alzheimer's disease |
AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
JP6582995B2 (en) * | 2014-01-21 | 2019-10-02 | 株式会社島津製作所 | Method for measuring APP-cleaved peptide |
US10035823B2 (en) | 2014-09-29 | 2018-07-31 | The Regents Of The University Of California | Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions |
ES2663623T3 (en) * | 2015-01-12 | 2018-04-16 | Heraeus Deutschland GmbH & Co. KG | Use of an electrically conductive composition as an electrically conductive adhesive to mechanically and electrically connect electrical conductors with the solar cell electrical contacts |
EP3324186B1 (en) | 2016-11-21 | 2020-09-16 | Ruhr-Universität Bochum | Method for the preselection of drugs for protein misfolding diseases |
JP7317016B2 (en) | 2017-12-19 | 2023-07-28 | スロゼン オペレーティング, インコーポレイテッド | Anti-LRP5/6 Antibodies and Methods of Use |
EP3732201A4 (en) * | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | Wnt surrogate molecules and uses thereof |
WO2019126399A1 (en) * | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
TW202300517A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-amyloid beta antibodies and uses thereof |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1308461A2 (en) * | 1993-01-25 | 2003-05-07 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
WO2003040183A2 (en) * | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
WO2003077858A2 (en) * | 2002-03-12 | 2003-09-25 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2004080419A2 (en) * | 2003-03-12 | 2004-09-23 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
DE19926068C1 (en) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteins of the bilin binding protein |
WO2001042306A2 (en) | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
AU4178601A (en) | 2000-02-24 | 2001-09-03 | Univ Washington | Humanized antibodies that sequester abeta peptide |
US20030083277A1 (en) | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
CA2407910C (en) * | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
EP1172378A1 (en) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
JP4317010B2 (en) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | Stable lyophilized pharmaceutical formulation of IgG antibody |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
US20050227941A1 (en) | 2001-12-17 | 2005-10-13 | Karen Duff | Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
AU2003270643A1 (en) | 2002-09-12 | 2004-04-30 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
AU2003279728B2 (en) | 2002-10-01 | 2007-09-27 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
JP2006519762A (en) | 2002-10-09 | 2006-08-31 | ライナット ニューロサイエンス コーポレイション | Methods for treating Alzheimer's disease using antibodies against amyloid β peptide and compositions thereof |
US20050106626A1 (en) | 2002-10-20 | 2005-05-19 | George Pieczenik | Ligand binding of amyloid peptide protein epitope |
CA2505991C (en) * | 2002-11-15 | 2018-02-27 | Genmab A/S | Human monoclonal antibodies against cd25 |
AU2003303198A1 (en) | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
WO2005025616A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
JP2007527865A (en) | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloid formed from proteins with various sequences |
AR047729A1 (en) * | 2003-11-28 | 2006-02-15 | Astrazeneca Ab | THERAPEUTIC ANTIBODIES THAT BIND APOLIPOPROTEIN E (APOE) |
ATE534667T1 (en) | 2004-02-23 | 2011-12-15 | Lilly Co Eli | ANTI-ABETA ANTIBODIES |
SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US20080287309A1 (en) | 2004-07-10 | 2008-11-20 | Alexion Pharmaceuticals, Inc. | Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
AR051800A1 (en) * | 2004-12-15 | 2007-02-07 | Wyeth Corp | BETA ANTIBODIES USED TO IMPROVE COGNITION |
PT1838733E (en) * | 2004-12-21 | 2011-12-13 | Medimmune Ltd | Antibodies directed to angiopoietin-2 and uses thereof |
AU2006208226A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
KR20070107079A (en) | 2005-01-28 | 2007-11-06 | 와이어쓰 | Stabilized liquid polypeptide formulations |
EP2204381A1 (en) | 2005-03-05 | 2010-07-07 | Abbott GmbH & Co. KG | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
ES2318918B1 (en) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | HUMAN ANTIBODIES WITH CAPACITY OF UNION TO THE BETA-AMYLOID PEPTIDE AND ITS APPLICATIONS. |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
US9133267B2 (en) | 2005-11-22 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | Antibody treatment of Alzheimer's and related diseases |
PT1976877E (en) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Monoclonal antibodies against amyloid beta protein and uses thereof |
CA2632822C (en) | 2005-12-12 | 2018-08-28 | Ruth Greferath | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
EP2325209A3 (en) | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
WO2008087184A2 (en) * | 2007-01-17 | 2008-07-24 | Merck Serono S.A. | Process for the purification of fc-containing proteins |
AU2009211635B2 (en) * | 2008-02-08 | 2014-06-26 | Immunas Pharma, Inc. | Antibody capable of binding specifically to Abeta-oligomer, and use thereof |
-
2008
- 2008-01-11 WO PCT/IB2008/000456 patent/WO2008084402A2/en active Application Filing
- 2008-01-11 EP EP08719192.0A patent/EP2104682B1/en active Active
- 2008-01-11 JP JP2009545252A patent/JP2010515717A/en active Pending
- 2008-01-11 AU AU2008204335A patent/AU2008204335B2/en not_active Ceased
- 2008-01-11 TW TW097101288A patent/TW200844110A/en unknown
- 2008-01-11 ES ES08719192.0T patent/ES2610474T3/en active Active
- 2008-01-11 CA CA2675340A patent/CA2675340C/en active Active
- 2008-01-11 DK DK08719192.0T patent/DK2104682T3/en active
- 2008-01-11 PL PL08719192T patent/PL2104682T3/en unknown
- 2008-01-11 US US12/013,185 patent/US7939075B2/en active Active
- 2008-01-11 SI SI200831731A patent/SI2104682T1/en unknown
-
2011
- 2011-04-05 US US13/079,852 patent/US8491903B2/en active Active
- 2011-04-05 US US13/079,886 patent/US20120040382A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1308461A2 (en) * | 1993-01-25 | 2003-05-07 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
WO2003040183A2 (en) * | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
WO2003077858A2 (en) * | 2002-03-12 | 2003-09-25 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO2004080419A2 (en) * | 2003-03-12 | 2004-09-23 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
Non-Patent Citations (10)
Title |
---|
ARBEL MICHAL ET AL: "Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 21, May 2005 (2005-05-01), pages 7718 - 7723, XP002500248, ISSN: 0027-8424 * |
BARD F ET AL: "Epitope and isotype specificities of antobodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 2023 - 2028, XP002982464, ISSN: 0027-8424 * |
BARD F ET AL: "Peripherally administered antibodies against amyloid beta- peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 8, 1 August 2000 (2000-08-01), pages 916 - 919, XP002154518, ISSN: 1078-8956 * |
GASKIN F ET AL: "HUMAN ANTIBODIES REACTIVE WITH BETA-AMYLOID PROTEIN IN ALZHEIMER'S DISEASE", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 177, no. 4, 1 April 1993 (1993-04-01), pages 1181 - 1186, XP001030627, ISSN: 0022-1007 * |
KOO EDWARD H ET AL: "Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 90, no. 10, 1993, pages 4748 - 4752, XP002434874, ISSN: 0027-8424 * |
LEE E B ET AL: "Targeting Amyloid-beta Peptide (Abeta) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Abeta Precursor Protein (APP) Transgenic Mice", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 281, no. 7, 17 February 2006 (2006-02-17), pages 4292 - 4299, XP003013340, ISSN: 0021-9258 * |
MARKARYAN ADAM ET AL: "Atypical processing of amyloid precursor fusion protein by proteolytic activity in Pichia pastoris", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 262, no. 1, 19 August 1999 (1999-08-19), pages 263 - 268, XP002441209, ISSN: 0006-291X * |
RAKOVER IDAN ET AL: "Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.", NEURO-DEGENERATIVE DISEASES 2007, vol. 4, no. 5, 25 May 2007 (2007-05-25), pages 392 - 402, XP009107314, ISSN: 1660-2854 * |
SCHMECHEL ARIANE ET AL: "Alzheimer beta-amyloid homodimers facilitate Abeta fibrillization and the generation of conformational antibodies.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 37, 12 September 2003 (2003-09-12), pages 35317 - 35324, XP002500246, ISSN: 0021-9258 * |
TAMURA YUICHI ET AL: "The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.", NEUROBIOLOGY OF DISEASE NOV 2005, vol. 20, no. 2, November 2005 (2005-11-01), pages 541 - 549, XP005118688, ISSN: 0969-9961 * |
Also Published As
Publication number | Publication date |
---|---|
EP2104682A2 (en) | 2009-09-30 |
DK2104682T3 (en) | 2017-01-16 |
WO2008084402A2 (en) | 2008-07-17 |
US8491903B2 (en) | 2013-07-23 |
SI2104682T1 (en) | 2017-05-31 |
US20120039897A1 (en) | 2012-02-16 |
TW200844110A (en) | 2008-11-16 |
US7939075B2 (en) | 2011-05-10 |
US20120040382A1 (en) | 2012-02-16 |
US20090028869A1 (en) | 2009-01-29 |
EP2104682B1 (en) | 2016-09-21 |
ES2610474T3 (en) | 2017-04-27 |
WO2008084402A8 (en) | 2009-08-27 |
JP2010515717A (en) | 2010-05-13 |
AU2008204335B2 (en) | 2013-06-13 |
CA2675340C (en) | 2018-07-31 |
AU2008204335A1 (en) | 2008-07-17 |
CA2675340A1 (en) | 2008-07-17 |
PL2104682T3 (en) | 2017-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008084402A3 (en) | Diagnosis and treatment of alzheimer's and other neurodementing diseases | |
MY148086A (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
MX2009003468A (en) | Antibodies. | |
EP2650308A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
MX358175B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties. | |
WO2008067464A3 (en) | NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES | |
MX2009013503A (en) | Monoclonal anti beta amyloid antibody. | |
EP2987807A3 (en) | Antibodies recognising phospho-tau | |
WO2008150946A8 (en) | HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF | |
UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
EP2426143A3 (en) | Method of providing disease-specific binding molecules and targets | |
UA101167C2 (en) | Pharmaceutical composition useful for the treatment of ocular disease | |
MX2009012950A (en) | Humanized antibodies to aã(20-42) globulomer and uses thereof. | |
WO2011045415A3 (en) | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases | |
EP2730659A3 (en) | Treatment and Prophylaxis of Amyloidosis | |
WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
NZ595387A (en) | Peptides for treatment and diagnosis of autoimmune disease | |
WO2005011599A3 (en) | Antibodies specific for toxic amyloid beta protein oligomers | |
MX341369B (en) | Safe and functional humanized anti beta-amyloid antibody. | |
MX2012014739A (en) | Novel antibody for the diagnosis and/or prognosis of cancer. | |
WO2009149485A3 (en) | Compounds for treating amyloidoses | |
WO2008042024A3 (en) | Neuroactive fragments of app | |
TN2014000458A1 (en) | Anti -transglutaminase 2 antibodies | |
JO3188B1 (en) | Antigen binding proteins specific for serum amyloid p component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08719192 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009545252 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2675340 Country of ref document: CA Ref document number: 2008204335 Country of ref document: AU Ref document number: MX/A/2009/007450 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008204335 Country of ref document: AU Date of ref document: 20080111 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2008719192 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008719192 Country of ref document: EP |